J Ellis1, K West, V Cortese, C Konoby, D Weigel. 1. Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada.
Abstract
OBJECTIVE: To determine the effect of maternally derived antibodies on induction of protective immune responses against bovine viral diarrhea virus (BVDV) type II in young calves vaccinated with a modified-live bovine viral diarrhea virus (BVDV) type I vaccine. DESIGN: Blinded controlled challenge study. ANIMALS: 24 neonatal Holstein and Holstein-cross calves that were deprived of maternal colostrum and fed pooled colostrum that contained a high concentration of (n = 6) or no (18) antibodies to BVDV. PROCEDURE: At 10 to 14 days of age, 6 seropositive and 6 seronegative calves were given a combination vaccine containing modified-live BVDV type I. All calves were kept in isolation for 4.5 months. Six calves of the remaining 12 untreated calves were vaccinated with the same combination vaccine at approximately 4 months of age. Three weeks later, all calves were challenged intranasally with a virulent BVDV type II. RESULTS: Seronegative unvaccinated calves and seropositive calves that were vaccinated at 2 weeks of age developed severe disease, and 4 calves in each of these groups required euthanasia. Seronegative calves that were vaccinated at 2 weeks or 4 months of age developed only mild or no clinical signs of disease. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicate that a single dose of a modified-live BVDV type-I vaccine given at 10 to 14 days of age can protect susceptible young calves from virulent BVDV type II infection for at least 4 months, but high concentrations of BVDV-specific maternally derived antibodies can block the induction of the response.
OBJECTIVE: To determine the effect of maternally derived antibodies on induction of protective immune responses against bovine viral diarrhea virus (BVDV) type II in young calves vaccinated with a modified-live bovine viral diarrhea virus (BVDV) type I vaccine. DESIGN: Blinded controlled challenge study. ANIMALS: 24 neonatal Holstein and Holstein-cross calves that were deprived of maternal colostrum and fed pooled colostrum that contained a high concentration of (n = 6) or no (18) antibodies to BVDV. PROCEDURE: At 10 to 14 days of age, 6 seropositive and 6 seronegative calves were given a combination vaccine containing modified-live BVDV type I. All calves were kept in isolation for 4.5 months. Six calves of the remaining 12 untreated calves were vaccinated with the same combination vaccine at approximately 4 months of age. Three weeks later, all calves were challenged intranasally with a virulent BVDV type II. RESULTS: Seronegative unvaccinated calves and seropositive calves that were vaccinated at 2 weeks of age developed severe disease, and 4 calves in each of these groups required euthanasia. Seronegative calves that were vaccinated at 2 weeks or 4 months of age developed only mild or no clinical signs of disease. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicate that a single dose of a modified-live BVDV type-I vaccine given at 10 to 14 days of age can protect susceptible young calves from virulent BVDV type II infection for at least 4 months, but high concentrations of BVDV-specific maternally derived antibodies can block the induction of the response.
Authors: Nathan Erickson; John Ellis; Cheryl Waldner; Herbert Lardner; Sheryl Gow; John Campbell; Adam Berenik Journal: Can Vet J Date: 2020-05 Impact factor: 1.008
Authors: Andrea Pecora; María Sol Pérez Aguirreburualde; Alejandra Aguirreburualde; Maria Rosa Leunda; Anselmo Odeon; Sebastián Chiavenna; Diego Bochoeyer; Marcelo Spitteler; Jorge L Filippi; Maria J Dus Santos; Susana M Levy; Andrés Wigdorovitz Journal: Vet Res Commun Date: 2012-05-26 Impact factor: 2.459
Authors: Nathan E N Erickson; Adam Berenik; Herbert Lardner; Stacey Lacoste; John Campbell; Sheryl Gow; Cheryl Waldner; John Ellis Journal: Can Vet J Date: 2021-01 Impact factor: 1.008
Authors: Nathan Erickson; John Ellis; Cheryl Waldner; Herbert Lardner; Sheryl Gow; John Campbell; Adam Berenik Journal: Can Vet J Date: 2020-08 Impact factor: 1.008
Authors: Manuel F Chamorro; Paul H Walz; Thomas Passler; Edzard van Santen; Julie Gard; Soren P Rodning; Kay P Riddell; Patricia K Galik; Yijing Zhang Journal: BMC Vet Res Date: 2015-02-10 Impact factor: 2.741
Authors: Shehnaz Lokhandwala; Xin Fang; Suryakant D Waghela; Jocelyn Bray; Leo M Njongmeta; Andy Herring; Karim W Abdelsalam; Christopher Chase; Waithaka Mwangi Journal: PLoS One Date: 2017-01-18 Impact factor: 3.240